Analysis of the Clinical Efficacy of Jianpi Yangwei Formula Combined with Sintilimab in Patients with Spleen and Stomach Deficiency Syndrome in Advanced Gastric Cancer
Objective To analyze the clinical efficacy of Jianpi Yangwei Formula combined with Sintilimab in the treatment of patients with spleen and stomach deficiency syndrome in advanced gastric cancer.Methods A total of 177 patients with spleen and stomach deficiency syndrome in advanced gastric cancer admitted to Nanyang Central Hospital from March 2022 to February 2023 were selected.According to the treatment plan,they were divided into a control group(routine chemotherapy+Sintilimab)and an observation group(routine chemotherapy+Sintilimab+Jianpi Yangwei Formula).The clinical efficacy differences between the two groups were compared after six treatment cycles.Changes in TCM syndrome scores,serum tumor markers,and nutritional status before and after treatment were analyzed,and the incidence of adverse reactions during treatment was recorded.Results The clinical remission rate and total effective rate of the observation group were significantly better than those of the control group,with statistically significant differences(P＜0.05).Before treatment,there were no statistically significant differences in TCM syndrome scores,serum carcinoembryonic antigen(CEA),cancer antigen 125(CA-125),cancer antigen 199(CA-199),cancer antigen 242(CA-242),cancer antigen 724(CA-724),body mass index(BMI),Human Serum Albumin(HSA),and total protein(TP)between the two groups(P＞0.05).After treatment,TCM syndrome scores,CEA,CA-125,CA-199,CA-242,and CA-724 in both groups were significantly reduced,and the observation group's scores were lower than those of the control group,with statistically significant differences(P＜0.05).After treatment,BMI,HSA,and TP levels in both groups significantly increased,and the observation group's levels were higher than those of the control group,with statistically significant differences(P＜0.05).The incidence of adverse reactions in the observation group was significantly lower than that in the control group,with statistically significant differences(P＜0.05).Conclusion Jianpi Yangwei Formula combined with Sintilimab helps improve the clinical treatment effect of patients with spleen and stomach deficiency syndrome in advanced gastric cancer,effectively improves the nutritional status of patients,reduces the incidence of adverse reactions during treatment,and has an ideal application effect.
国家科技期刊平台
NSTL
万方数据
